Fosfomycin and tobramycin in combination downregulate nitrate reductase genes narG and narH, resulting in increased activity against Pseudomonas aeruginosa under anaerobic conditions

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 11, 2013, Pages 5406-5414

  McCaughey, Gerard ^a   Gilpin, Deirdre F ^a   Schneiders, Thamarai ^b   Hoffman, Lucas R ^c   McKevitt, Matt ^d   Elborn, J Stuart ^a,b   Tunney, Michael M ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d GILEAD SCIENCES INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FOSFOMYCIN; NITRATE REDUCTASE NARG; NITRATE REDUCTASE NARH; OXIDOREDUCTASE; TOBRAMYCIN; UNCLASSIFIED DRUG;

ANAEROBIC GROWTH; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATION; CYSTIC FIBROSIS; ESSENTIAL GENE; MICROARRAY ANALYSIS; MUTANT; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RECEPTOR DOWN REGULATION; TRANSPOSON;

ANAEROBIOSIS; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; CYSTIC FIBROSIS; DRUG COMBINATIONS; FOSFOMYCIN; GENE EXPRESSION REGULATION, BACTERIAL; HUMANS; ISOENZYMES; LUNG; MICROBIAL SENSITIVITY TESTS; NITRATE REDUCTASE; NITRATES; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; TOBRAMYCIN; TRANSCRIPTION, GENETIC;

EID: 84885899872     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00750-13     Document Type: Article

References (45)

1. Tunney MM, Field TR, Moriarty TF, Patrick S, Doering G, Muhlebach MS, Wolfgang MC, Boucher R, Gilpin DF, McDowell A, Elborn JS. 2008. Detection of anaerobic bacteria in high numbers in sputum from patients with cystic fibrosis. Am. J. Respir. Crit. Care Med. 177:995-1001.
2. Tunney MM, Klem ER, Fodor AA, Gilpin DF, Moriarty TF, McGrath SJ, Muhlebach MS, Boucher RC, Cardwell C, Doering G, Elborn JS, Wolfgang MC. 2011. Use of culture and molecular analysis to determine the effect of antibiotic treatment on microbial community diversity and abundance during exacerbation in patients with cystic fibrosis. Thorax 66:579-584.
3. Foweraker JE, Laughton CR, Brown DF, Bilton D. 2009. Comparison of methods to test antibiotic combinations against heterogeneous populations of multiresistant Pseudomonas aeruginosa from patients with acute infective exacerbations in cystic fibrosis. Antimicrob. Agents Chemother. 53:4809-4815.
4. Schreiber K, Krieger R, Benkert B, Eschbach M, Arai H, Schobert M, Jahn D. 2007. The anaerobic regulatory network required for Pseudomonas aeruginosa nitrate respiration. J. Bacteriol. 189:4310-4314.
5. Palmer KL, Brown SA, Whiteley M. 2007. Membrane-bound nitrate reductase is required for anaerobic growth in cystic fibrosis sputum. J. Bacteriol. 189:4449-4455.
6. King P, Citron DM, Griffith DC, Lomovskaya O, Dudley MN. 2010. Effect of oxygen limitation on the in vitro activity of levofloxacin and other antibiotics administered by the aerosol route against Pseudomonas aeruginosa from cystic fibrosis patients. Diagn. Microbiol. Infect. Dis. 66: 181-186.
7. Hill D, Rose B, Pajkos A, Robinson M, Bye P, Bell S, Elkins M, Thompson B, Macleod C, Aaron SD, Harbour C. 2005. Antibiotic susceptabilities of Pseudomonas aeruginosa isolates derived from patients with cystic fibrosis under aerobic, anaerobic, and biofilm conditions. J. Clin. Microbiol. 43:5085-5090.
8. Field TR, White A, Elborn JS, Tunney MM. 2005. Effect of oxygen limitation on the in vitro antimicrobial susceptibility of clinical isolates of Pseudomonas aeruginosa grown planktonically and as biofilms. Eur. J. Clin. Microbiol. Infect. Dis. 24:677-687.
9. Strateva T, Yordanov D. 2009. Pseudomonas aeruginosa-A phenomenon of bacterial resistance. J. Med. Microbiol. 58:1133-1148.
10. Rao P, McCaughan J, McCalmont M, Goldsmith CE, Hall V, Millar BC, McCann MA, Downey DG, Rendall JC, Elborn JS, Moore JE. 2012. Comparison of antibiotic susceptibility patterns in Pseudomonas aeruginosa isolated from adult patients with cystic fibrosis (CF) with invasive Pseudomonas aeruginosa from non-CF patients. J. Cyst. Fibros. 11:349-352.
11. Ashish A, Shaw M, Winstanley C, Ledson MJ, Walshaw MJ. 2012. Increasing resistance of the Liverpool epidemic strain (LES) of Pseudomonas aeruginosa (Psa) to antibiotics in cystic fibrosis (CF)-A cause for concern? J. Cyst. Fibros. 11:173-179.
12. McCaughey G, McKevitt M, Elborn JS, Tunney MM. 2012. Antimicrobial activity of fosfomycin and tobramycin in combination against cystic fibrosis pathogens under aerobic and anaerobic conditions. J. Cyst. Fibros. 11:163-172.
13. Jacobs MA, Alwood A, Thaipisuttikul I, Spencer D, Haugen E, Ernst S, Will O, Kaul R, Raymond C, Levy R, Chun-Rong L, Guenthner D, Bovee D, Olson MV, Manoil C. 2003. Comprehensive transposon mutant library of Pseudomonas aeruginosa. Proc. Natl. Acad. Sci. U. S. A. 100:14339-14344.
14. D'Argenio DA, Wu M, Hoffman LR, Kulasekara HD, Deziel E, Smith EE, Nguyen H, Ernst RK, Larson Freeman TJ, Spencer DH, Brittnacher M, Hayden HS, Selgrade S, Klausen M, Goodlett DR, Burns JL, Ramsey BW, Miller SI. 2007. Growth phenotypes of Pseudomonas aeruginosa lasR mutants adapted to the airways of cystic fibrosis patients. Mol. Microbiol. 64:512-533.
15. Filiatrault MJ, Picardo KF, Ngai H, Passador L, Iglewski BH. 2006. Identification of Pseudomonas aeruginosa genes involved in virulence and anaerobic growth. Infect. Immun. 74:4237-4245.
16. Van Alst NE, Sherrill LA, Iglewski BH, Haidaris CG. 2009. Compensatory periplasmic nitrate reductase activity supports anaerobic growth of Pseudomonas aeruginosa PAO1 in the absence of membrane nitrate reductase. Can. J. Microbiol. 55:1133-1144.
17. Eschbach M, Schreiber K, Trunk K, Buer J, Jahn D, Schobert M. 2004. Long-Term anaerobic survival of the opportunistic pathogen Pseudomonas aeruginosa via pyruvate fermentation. J. Bacteriol. 186:4596-4604.
18. Hoffman LR, Kulasekara HD, Emerson J, Houston LS, Burns JL, Ramsey BW, Miller SI. 2009. Pseudomonas aeruginosa lasR mutants are associated with cystic fibrosis lung disease progression. J. Cyst. Fibros. 8:66-70.
19. Hoffman LR, Richardson AR, Houston LS, Kulasekara HD, Martens-Habbena W, Klausen M, Burns JL, Stahl DA, Hassett DJ, Fang FC, Miller SI. 2010. Nutrient availability as a mechanism for selection of antibiotic tolerant Pseudomonas aeruginosa within the CF airway. PLoS Pathog. 6:e1000712. doi:10.1371/journal. ppat.1000712.
20. Smith EE, Buckley DG, Wu Z, Saenphimmachak C, Hoffman LR, D'Argenio DA, Miller SI, Ramsey BW, Speert DP, Moskowitz SM, Burns JL, Kaul R, Olson MV. 2006. Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients. Proc. Natl. Acad. Sci. U. S. A. 103:8487-8492.
21. Yoon SS, Coakley R, Lau GW, Lymar SV, Gaston B, Karabulut AC, Hennigan RF, Hwang SH, Buettner G, Schurr MJ, Mortensen JE, Burns JL, Speert D, Boucher RC, Hassett DJ. 2006. Anaerobic killing of mucoid Pseudomonas aeruginosa by acidified nitrite derivatives under cystic fibrosis airway conditions. J. Clin. Invest. 116:436-446.
22. Moreno-Vivián C, Cabello P, Martínez-Luque M, Blasco R, Castillo F. 1999. Prokaryotic nitrate reduction: Molecular properties and functional distinction among bacterial nitrate reductases. J. Bacteriol. 181:6573-6584.
23. Goh E-B, Bledsoe PJ, Chen L-L, Gyaneshwar P, Stewart V, Igo MM. 2005. Hierarchical control of anaerobic gene expression in Escherichia coli K-12: The nitrate-responsive NarX-NarL regulatory system represses synthesis of the fumarate-responsive DcuS-DcuR regulatory system. J. Bacteriol. 187:4890-4899.
24. Jones SA, Gibson T, Maltby RC, Chowdhury FZ, Stewart V, Cohen PS, Conway T. 2011. Anaerobic respiration of Escherichia coli in the mouse intestine. Infect. Immun. 79:4218-4226.
25. Wang W, Richardson AR, Martens-Habbena W, Stahl DA, Fang FC, Hansen EJ. 2008. Identification of a repressor of a truncated denitrification pathway in Moraxella catarrhalis. J. Bacteriol. 190:7762-7772.
26. Sohaskey CD, Wayne LG. 2003. Role of narK2X and narGHJI in hypoxic upregulation of nitrate reduction by Mycobacterium tuberculosis. J. Bacteriol. 185:7247-7256.
27. Winter SE, Winter MG, Xavier MN, Thiennimitr P, Poon V, Keestra AM, Laughlin RC, Gomez G, Wu J, Lawhon SD, Popova IE, Parikh SJ, Adams LG, Tsolis RM, Stewart VJ, Bäumler AJ. 2013. Host-derived nitrate boosts growth of E. coli in the inflamed gut. Science 339:708-711.
28. Son MS, Matthews WJ, Jr, Kang Y, Nguyen DT, Hoang TT. 2007. In vivo evidence of Pseudomonas aeruginosa nutrient acquisition and pathogenesis in the lungs of cystic fibrosis patients. Infect. Immun. 75:5313-5324.
29. Ka J-O, Urbance J, Ye RW, Ahn T-Y, Tiedje JM. 1997. Diversity of oxygen and N-oxide regulation of nitrite reductases in denitrifying bacteria. FEMS Microbiol. Lett. 156:55-60.
30. Chen F, Xia Q, Ju LK. 2006. Competition between oxygen and nitrate respirations in continuous culture of Pseudomonas aeruginosa performing aerobic denitrification. Biotechnol. Bioeng. 93:1069-1078.
31. Alvarez-Ortega C, Harwood CS. 2007. Responses of Pseudomonas aeruginosa to low oxygen indicate that growth in the cystic fibrosis lung is by aerobic respiration. Mol. Microbiol. 65:153-165.
32. Wagner VE, Bushnell D, Passador L, Brooks AI, Iglewski BH. 2003. Microarray analysis of Pseudomonas aeruginosa quorum-sensing regulons: Effects of growth phase and environment. J. Bacteriol. 185:2080-2095.
33. Filiatrault MJ, Wagner VE, Bushnell D, Haidaris CG, Iglewski BH, Passador L. 2005. Effect of anaerobiosis and nitrate on gene expression in Pseudomonas aeruginosa. Infect. Immun. 73:3764-3772.
34. Platt MD, Schurr MJ, Sauer K, Vazquez G, Kukavica-Ibrulj I, Potvin E, Levesque RC, Fedynak A, Brinkman FSL, Schurr J, Hwang S-H, Lau GW, Limbach PA, Rowe JJ, Lieberman MA, Barraud N, Webb J, Kjelleberg S, Hunt DF, Hassett DJ. 2008. Proteomic, microarray, and signature-Tagged mutagenesis analyses of anaerobic Pseudomonas aeruginosa at pH 6.5, likely representing chronic, late-stage cystic fibrosis airway conditions. J. Bacteriol. 190:2739-2758.
35. Couce A, Briales A, Rodriguez-Rojas A, Costas C, Pascual A, Blazquez J. 2012. Genomewide overexpression screen for fosfomycin resistance in Escherichia coli: MurA confers clinical resistance at low fitness cost. Antimicrob. Agents Chemother. 56:2767-2769.
36. Takahata S, Ida T, Hiraishi T, Sakakibara S, Maebashi K, Terada S, Muratani T, Matsumoto T, Nakahama C, Tomono K. 2010. Molecular mechanisms of fosfomycin resistance in clinical isolates of Escherichia coli. Int. J. Antimicrob. Agents 35:333-337.
37. Petek M, Baebler S, Kuzman D, Rotter A, Podlesek Z, Gruden K, Ravnikar M, Urleb U. 2010. Revealing fosfomycin primary effect on Staphylococcus aureus transcriptome: Modulation of cell envelope biosynthesis and phosphoenolpyruvate induced starvation. BMC Microbiol. 10:159.
38. Castañeda-García A, Rodríguez-Rojas A, Guelfo JR, Blázquez J. 2009. The glycerol-3-phosphate permease GlpT is the only fosfomycin transporter in Pseudomonas aeruginosa. J. Bacteriol. 191:6968-6974.
39. Nilsson AI, Berg OG, Aspevall O, Kahlmeter G, Andersson DI. 2003. Biological costs and mechanisms of fosfomycin resistance in Escherichia coli. Antimicrob. Agents Chemother. 47:2850-2858.
40. Macleod DL, Velayudhan J, Kenney TF, Therrien JH, Sutherland JL, Barker LM, Baker WR. 2012. Fosfomycin enhances the active transport of tobramycin in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 56:1529-1538.
41. Taber HW, Mueller JP, Miller PF, Arrow AS. 1987. Bacterial uptake of aminoglycoside antibiotics. Microbiol. Rev. 51:439-457.
42. Ma JF, Hager PW, Howell ML, Phibbs PV, Hassett DJ. 1998. Cloning and characterization of the Pseudomonas aeruginosa zwf gene encoding glucose-6-phosphate dehydrogenase, an enzyme important in resistance to methyl viologen (paraquat). J. Bacteriol. 180:1741-1749.
43. Silo-Suh L, Suh SJ, Phibbs PV, Ohman DE. 2005. Adaptations of Pseudomonas aeruginosa to the cystic fibrosis lung environment can include deregulation of zwf, encoding glucose-6-phosphate dehydrogenase. J. Bacteriol. 187:7561-7568.
44. Kohanski MA, Dwyer DJ, Hayete B, Lawrence CA, Collins JJ. 2007. A common mechanism of cellular death induced by bactericidal antibiotics. Cell 130:797-810.
45. Wang X, Zhao X. 2009. Contribution of oxidative damage to antimicrobial lethality. Antimicrob. Agents Chemother. 53:1395-1402.